Case Report: Daily CBD Administration Associated With Remission Of Schizophrenic Symptoms

GERMANY: The adjunctive use of cannabidiol is associated with a remission in schizophrenic symptoms in a patient previously unresponsive to conventional treatment, according to a case report published in the Australian & New Zealand Journal of Psychiatry.

Investigators from the University of Leipzig in Germany assessed the use of twice-daily dosing of 750mg of CBD in conjunction with clozapine in a patient with treatment-resistant schizophrenia. Cannabidiol dosing was associated with remission criteria and improvements remained consistent over eight months.

“Our case report contradicts the assumption that CBD is not likely to be any superior than existing antipsychotics,” authors concluded. “In fact, CBD might be particularly suitable for those patients [who are] resistant to antipsychotics due to its different mode of action.”


For more information, contact Paul Armentano, NORML Deputy Director, at: paul@norml.org. Full text of the study, “Remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol,” appears in the Australian & New Zealand Journal of Psychiatry.

Comparing Adverse Effects of Marijuana, Alcohol

NEW YORK: The emerging debate about whether marijuana is “safer” than other substances has led to a new study documenting how alcohol and marijuana use impacts the psychosocial well-being of high school seniors.

Researchers affiliated with New York University published the study online ahead of print in the American Journal of Drug and Alcohol Abuse. Investigators analyzed data from a nationally representative sample of high school seniors in the Monitoring the Future (MTF) study.   MTF is a nation-wide ongoing annual study of the behaviors, attitudes, and values of American secondary school students.

Students were asked to indicate whether they experienced various adverse psychosocial outcomes resulting from use of each substance. The authors analyzed data from 7,437 students (modal age: 18) from cohorts assessed from 2007 through 2011 who reported using alcohol or marijuana in their lifetime.

“The paucity of research is of particular public health concern as alcohol and marijuana are the two most commonly used psychoactive substances among adolescents,” said Joseph J. Palamar, Ph.D., M.P.H.

Forget Marijuana Madness: Could Marijuana Treat Your Depression

NETHERLANDS: Depending on who you listen to, marijuana could be the solution for whatever ails you or your ultimate demise; or it could make you dumb and sick. We have a tendency to believe the research not funded by biased parties in support of federal marijuana prohibition—the research that shows cannabis may reduce the risk of Alzheimer’s and obesity, kill cancer cells, and even treat depression. [Read more…]